Change of Nomad and Broker

RNS Number : 7601X

Advanced Oncotherapy PLC

16 January 2014

 



16 January 14

Advanced Oncotherapy Plc

("Advanced Oncotherapy" or the "Company")

Change of Nomad and Broker

Advanced Oncotherapy (AIM: AVO) is pleased to announce the appointment of Westhouse Securities Limited as the Company's Nominated Adviser and Joint Broker with immediate effect.

For further information please visit www.advancedoncotherapy.com or contact:

Advanced Oncotherapy Plc	Tel: [phone]
Michael Sinclair, CEO
Westhouse Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi David Coaten
Peterhouse Corporate Finance (Joint Broker)	Tel: [phone]
Jon Levinson Lucy Williams
Tavistock Communications (Financial PR & IR)	Tel: [phone]
Simon Hudson

About Advanced Oncotherapy Plc

1.    AVO is a provider of radiotherapy services that harnesses the best in modern technology.  As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2.    AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT.  This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3.    AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

 

END

 

 

APPBLGDBBGBBGSU